Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yasuki Kamai

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Nature Communications

English

Efficacy of CS-834 Against Experimental Pneumonia Caused by Penicillin-Susceptible and -ResistantStreptococcus Pneumoniae in Mice

Antimicrobial Agents and Chemotherapy

Infectious Diseases

Pharmacology

1998

English

Related publications

P-Loop Conformation Governed Crizotinib Resistance in G2032r-Mutated ROS1 Tyrosine Kinase: Clues From Free Energy Landscape

PLoS Computational Biology

Molecular Neuroscience

English

ROS1-ADGRG6: A Case Report of a Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib

English

P075 Hippo-Yap Pathway Mediated Resistance to Crizotinib in ROS1-Positive Lung Cancer

Journal of Thoracic Oncology

English

Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion

Journal of Thoracic Oncology

English

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

Journal of Thoracic Oncology

English

E-Cadherin/Ros1 Inhibitor Synthetic Lethality in Breast Cancer

Cancer Discovery

Oncology

2018

English

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

Journal of Thoracic Oncology

English

The HSP90 Inhibitor Ganetespib Synergizes With the MET Kinase Inhibitor Crizotinib in Both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Cancer Research

Oncology

2013

English

ROS1 Rearrangements Are Only Found in Lung Adenocarcinomas With Diffuse Strong IHC Expression of ROS1

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Yasuki Kamai

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Efficacy of CS-834 Against Experimental Pneumonia Caused by Penicillin-Susceptible and -ResistantStreptococcus Pneumoniae in Mice

Related publications

P-Loop Conformation Governed Crizotinib Resistance in G2032r-Mutated ROS1 Tyrosine Kinase: Clues From Free Energy Landscape

ROS1-ADGRG6: A Case Report of a Novel ROS1 Oncogenic Fusion Variant in Lung Adenocarcinoma and the Response to Crizotinib

P075 Hippo-Yap Pathway Mediated Resistance to Crizotinib in ROS1-Positive Lung Cancer

Clinical Activity of Crizotinib in Lung Adenocarcinoma Harboring a Rare ZCCHC8-ROS1 Fusion

OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC

E-Cadherin/Ros1 Inhibitor Synthetic Lethality in Breast Cancer

Crizotinib Improves Osteoarthritis Symptoms in a ROS1-Fusion Advanced Non–Small Cell Lung Cancer Patient

The HSP90 Inhibitor Ganetespib Synergizes With the MET Kinase Inhibitor Crizotinib in Both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

ROS1 Rearrangements Are Only Found in Lung Adenocarcinomas With Diffuse Strong IHC Expression of ROS1